[1] |
LIN H, ZHANG X, LI G, et al. Epidemiology and clinical outcomes of metabolic (dysfunction)-associated fatty liver disease[J]. J Clin Transl Hepatol, 2021, 9(6): 972-982. DOI: 10.14218/JCTH.2021.00201.
|
[2] |
CAI LY, WANG WJ, LIANG YX, et al. Research progress in the relationship between metabolic associated fatty liver disease and metabolic syndrome[J]. Chin J New Clin Med, 2021, 14(7): 730-734. DOI: 10.3969/j.issn.1674-3806.2021.07.22.
蔡联英, 王文娟, 梁运啸, 等. 代谢相关脂肪性肝病与代谢综合征相关性的研究进展[J]. 中国临床新医学, 2021, 14(7): 730-734. DOI: 10.3969/j.issn.1674-3806.2021.07.22.
|
[3] |
SHI WR, WANG HY, CHEN S, et al. Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study[J]. Lipids Health Dis, 2018, 17(1): 236. DOI: 10.1186/s12944-018-0886-2.
|
[4] |
LIU X, WU Q, YAN G, et al. Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype[J]. J Endocrinol Invest, 2021, 44(6): 1253-1261. DOI: 10.1007/s40618-020-01417-z.
|
[5] |
ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
|
[6] |
YU C, WANG M, ZHENG S, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese population: a population-based prospective cohort study[J]. J Clin Transl Hepatol, 2022, 10(1): 6-16. DOI: 10.14218/JCTH.2021.00089.
|
[7] |
XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
|
[8] |
SHENG G, LU S, XIE Q, et al. The usefulness of obesity and lipid-related indices to predict the presence of non-alcoholic fatty liver disease[J]. Lipids Health Dis, 2021, 20(1): 134. DOI: 10.1186/s12944-021-01561-2.
|
[9] |
DUAN SJ, LIU ZJ, CHEN JL, et al. Value of lipid accumulation product and visceral fat index in predicting non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38(1): 129-134. DOI: 10.3969/j.issn.1001-5256.2022.01.020.
段绍杰, 刘尊敬, 陈佳良, 等. 脂质蓄积指数、内脏脂肪指数对非酒精性脂肪性肝病的预测价值[J]. 临床肝胆病杂志, 2022, 38(1): 129-134. DOI: 10.3969/j.issn.1001-5256.2022.01.020.
|
[10] |
WANG J, SU Z, FENG Y, et al. Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China[J]. BMC Gastroenterol, 2021, 21(1): 482. DOI: 10.1186/s12876-021-02072-1.
|
[11] |
JIN T, CAO HH, ZHANG B, et al. Association of EGR1, UACR and CMI with non-alcoholic fatty liver disease in type 2 diabetic patients[J]. Hainan Med J, 2021, 32(23): 3003-3007. DOI: 10.3969/j.issn.1003-6350.2021.23.003.
金婷, 曹含弘, 张斌, 等. 2型糖尿病患者EGR1、UACR及CMI指数与非酒精性脂肪性肝病的关系[J]. 海南医学, 2021, 32(23): 3003-3007. DOI: 10.3969/j.issn.1003-6350.2021.23.003.
|
[12] |
LI YY, ZHAO L, DENG X, et al. Relationship between cardiometabolic index and risk of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Chin Gen Pract, 2021, 24(15): 1883-1888. DOI: 10.12114/j.issn.1007-9572.2021.00.433.
李彦彦, 赵丽, 邓霞, 等. 2型糖尿病患者心脏代谢指数与非酒精性脂肪性肝病的关系研究[J]. 中国全科医学, 2021, 24(15): 1883-1888. DOI: 10.12114/j.issn.1007-9572.2021.00.433.
|
[13] |
ZOU J, XIONG H, ZHANG H, et al. Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population[J]. BMC Gastroenterol, 2022, 22(1): 20. DOI: 10.1186/s12876-022-02099-y.
|
[14] |
LIU Y, WANG W. Sex-specific contribution of lipid accumulation product and cardiometabolic index in the identification of nonalcoholic fatty liver disease among Chinese adults[J]. Lipids Health Dis, 2022, 21(1): 8. DOI: 10.1186/s12944-021-01617-3.
|
[15] |
YANG Y, WANG B, YUAN H, et al. Triglycerides to high-density lipoprotein cholesterol ratio is the best surrogate marker for insulin resistance in nonobese middle-aged and elderly population: a cross-sectional study[J]. Int J Endocrinol, 2021, 2021: 6676569. DOI: 10.1155/2021/6676569.
|
[16] |
POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics[J]. Metabolism, 2019, 92: 82-97. DOI: 10.1016/j.metabol.2018.11.014.
|
[17] |
WANG YH, GAO Y. Research progress in diagnosis and treatment of non-alcoholic fatty liver disease combinated with type 2 diabetes mellitus[J]. J Jilin Univ(Med Edit), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.
王雨涵, 高影. 非酒精性脂肪性肝病并发2型糖尿病诊断和治疗的研究进展[J]. 吉林大学学报(医学版), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.
|
[18] |
SIMOES I, JANIKIEWICZ J, BAUER J, et al. Fat and sugar-a dangerous duet. a comparative review on metabolic remodeling in rodent models of nonalcoholic fatty liver disease[J]. Nutrients, 2019, 11(12): 2871. DOI: 10.3390/nu11122871.
|
[19] |
ALVES-BEZERRA M, COHEN DE. Triglyceride metabolism in the liver[J]. Compr Physiol, 2017, 8(1): 1-8. DOI: 10.1002/cphy.c170012.
|
[20] |
XIN Y, WANG Y, CHI J, et al. Elevated free fatty acid level is associated with insulin-resistant state in nondiabetic Chinese people[J]. Diabetes Metab Syndr Obes, 2019, 12: 139-147. DOI: 10.2147/DMSO.S186505.
|
[21] |
ZIOLKOWSKA S, BINIENDA A, JABKOWSKI M, et al. The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease[J]. Int J Mol Sci, 2021, 22(20): 11128. DOI: 10.3390/ijms222011128.
|
[22] |
SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci, 2021, 22(8): 4156. DOI: 10.3390/ijms22084156.
|
[23] |
HEEREN J, SCHEJA L. Metabolic-associated fatty liver disease and lipoprotein metabolism[J]. Mol Metab, 2021, 50: 101238. DOI: 10.1016/j.molmet.2021.101238.
|
[24] |
YU L, LI Y, DU C, et al. Pattern recognition receptor-mediated chronic inflammation in the development and progression of obesity-related metabolic diseases[J]. Mediators Inflamm, 2019, 2019: 5271295. DOI: 10.1155/2019/5271295.
|
[25] |
LIU J, LI YJ, RAO ZY. Correlation analysis of FibroScan measurements and body composition measure-ments in patients with nonalcoholic fatty liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31(12): 1108-1111. DOI: 10.3969/j.issn.1005-0264.2021.12.013.
刘婧, 李燕菊, 饶志勇. 非酒精性脂肪性肝病患者FibroScan指标与人体成分指标相关性分析[J]. 中西医结合肝病杂志, 2021, 31(12): 1108-1111. DOI: 10.3969/j.issn.1005-0264.2021.12.013.
|
[26] |
LIN MS, LIN TH, GUO SE, et al. Waist-to-height ratio is a useful index for nonalcoholic fatty liver disease in children and adolescents: a secondary data analysis[J]. BMC Public Health, 2017, 17(1): 851. DOI: 10.1186/s12889-017-4868-5.
|